• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect . Four Point-Of-Care Lateral Flow Immunoassays for Diagnosis of COVID-19 and for Assessing Dynamics of Antibody Responses to SARS-CoV-2

tetano

Editor, Senior Moderator
J Infect


. 2020 Jun 15;S0163-4453(20)30404-7.
doi: 10.1016/j.jinf.2020.06.023. Online ahead of print.
Four Point-Of-Care Lateral Flow Immunoassays for Diagnosis of COVID-19 and for Assessing Dynamics of Antibody Responses to SARS-CoV-2


Jhong-Lin Wu[SUP] 1 [/SUP], Wen-Pin Tseng[SUP] 1 [/SUP], Chien-Hao Lin[SUP] 1 [/SUP], Tai-Fen Lee[SUP] 2 [/SUP], Ming-Yi Chung[SUP] 2 [/SUP], Chien-Hua Huang[SUP] 1 [/SUP], Shey-Ying Chen[SUP] 3 [/SUP], Po-Ren Hsueh[SUP] 4 [/SUP], Shyr-Chyr Chen[SUP] 1 [/SUP]



Affiliations

Abstract

Objectives: We aimed to evaluate the role of rapid serological tests in the management of coronavirus disease 2019 (COVID-19) patients.
Methods: This retrospective study enrolled 16 real-time reverse transcription polymerase chain reaction-confirmed symptomatic patients with COVID-19 and 58 COVID-19 negative patients at a medical center in Taiwan over a 3-month period. Serial serum samples were collected and tested for antibody response using four point-of-care (POC) lateral flow immunoassays (LFIA) (ALLTEST 2019-nCoV IgG/IgM Rapid Test, Dynamiker 2019-nCoV IgG/IgM Rapid Test, ASK COVID-19 IgG/IgM Rapid Test, and Wondfo SARS-CoV-2 Antibody Test). Time-dependent detection sensitivity and timeliness of seroconversion were determined and compared between the four POC rapid tests.
Results: The overall sensitivity and specificity of the four tests for detecting anti-SARS-CoV-2 antibodies after 3 weeks of symptom onset were 100% and 100%, respectively. There was no significant difference between the rapid tests used for detection of IgM and IgG separately and those used for detection of combined total antibody (mainly IgM/IgG). There was no significant difference between the four POC rapid tests in terms of time required for determining seroconversion of COVID-19. Patients with COVID-19 with pneumonia demonstrated shorter seroconversion time than those without pneumonia.
Conclusion: Though the POC antibody rapid tests based on LFIA showed reliable performance in the detection of SARS-CoV-2-specific antibodies, the results of these tests should be interpreted and applied appropriately in the context of antibody dynamic of COVID-19 infection. COVID-19 patients complicated with pneumonia exhibited earlier anti-SARS-CoV-2 antibody response than COVID-19 patients without pneumonia.

Keywords: Antibody response; COVID-19 pandemic; Immunochromatographic assay; Lateral flow method; Rapid test.
 
Back
Top Bottom